Array BioPharma (ARRY) PT Raised to $24 at Jefferies

Jefferies analyst Eun Yang raised the price target on Array BioPharma (NASDAQ: ARRY) to $24.00 (from $21.00) while maintaining a Buy rating.

Yang notes the company narrowed its Q2 net loss of strong Braftovi/Mektovi sales.

You May Also Be Interested In

• Harley-Davidson (HOG) PT Raised to $33 at DA Davidson Amid Progress on Back to Bricks Strategy
• High Liner Foods Inc. (HLF:CN) (HLNFF) PT Raised to Cdn$17.50 at BMO Capital
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation